Eli Lilly Expands Infectious Disease Pipeline Through Strategic Biotech Acquisitions | iPharmaCenter

Eli Lilly has entered into three separate acquisition agreements aimed at strengthening its position in the infectious disease space, targeting both viral and bacterial threats associated with long-term health complications.

The deals involve Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc., marking a significant step in Lilly’s broader strategy to invest in innovative prevention-focused technologies.

These acquisitions reflect Lilly’s renewed emphasis on combating infectious diseases that contribute to chronic neurological conditions, cancer risks, and antimicrobial resistance. By integrating novel vaccine platforms and early-stage pipelines, the company aims to reduce disease burden through preventative interventions rather than treatment alone.

Curevo Acquisition Focuses on Improved Shingles Prevention

Curevo’s primary asset, amezosvatein, is an investigational shingles vaccine designed to enhance tolerability while maintaining strong immune protection. Although current shingles vaccines are effective, side effects often discourage patients from completing vaccination schedules, particularly the second dose.

Also read: FDA Approves Datroway as First TROP2-Directed ADC for First-Line Metastatic Triple-Negative Breast Cancer in Non-PD-1/PD-L1 Candidates

Amezosvatein incorporates a synthetic adjuvant intended to minimize adverse reactions. In comparative Phase 2 clinical data, the candidate demonstrated immune responses comparable to existing vaccines while significantly reducing common side effects such as fatigue, chills, and injection-site discomfort. This improved tolerability profile could increase vaccination uptake and broaden protection against shingles and its associated risks, including stroke and potential links to cognitive decline.

Under the agreement, Lilly will acquire Curevo, with total deal value reaching up to $1.5 billion, including upfront and milestone-based payments.

Also read: Europe’s Pharmaceutical Strategy in a Changing Global Order: Germany and France Push for Resilience and Competitiveness

LimmaTech Biologics Strengthens Bacterial Vaccine Development

LimmaTech Biologics is advancing vaccines targeting bacterial pathogens that are increasingly difficult to treat due to rising antimicrobial resistance. Its research focuses on organisms such as Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis, pathogens linked to severe infections and long-term health complications.

The company’s technology platform is designed to trigger broad and sustained immune responses by targeting bacterial toxins and superantigens. Its lead candidate, LTB-SA7, is currently in Phase 1 trials for preventing infections caused by S. aureus, a major contributor to post-surgical complications.

In addition to its lead program, LimmaTech is developing early-stage candidates addressing infections that disproportionately impact women, including those associated with infertility. Lilly will acquire LimmaTech for up to $780 million, contingent on clinical and regulatory milestones.

Vaccine Company Brings Next-Generation Viral Vaccine Platform

Vaccine Company contributes a proprietary in vivo nanoparticle (IVN) platform that enables efficient antigen presentation without the complexities of traditional virus-like particle manufacturing. This approach is designed to generate durable immune responses with improved scalability.

The company’s pipeline includes multiple viral targets, with a leading candidate focused on Epstein-Barr Virus (EBV). This program is preparing to enter Phase 1 clinical testing and incorporates a multi-antigen design aimed at comprehensive immune protection.

Growing scientific evidence links EBV infection to conditions such as multiple sclerosis and certain cancers. A preventive vaccine could therefore play a critical role not only in avoiding acute illness like infectious mononucleosis but also in reducing long-term disease risks.

Lilly’s acquisition of Vaccine Company is valued at up to $1.55 billion, including upfront consideration and additional payments tied to development and commercialization milestones.

Also read: Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial

Strategic Outlook: Eli Lilly focussing on Infectious Diseases

Through these acquisitions, Eli Lilly is reinforcing its long-term commitment to infectious disease prevention by investing in differentiated vaccine technologies. The combined pipelines address key global health challenges, including vaccine hesitancy, antimicrobial resistance, and virus-associated chronic diseases.

This expansion positions Lilly to compete more aggressively in the vaccine and infectious disease market while supporting broader public health goals through innovative, prevention-focused solutions.